Publication:
A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine

dc.contributor.authorTURANLI, BESTE
dc.contributor.authorARĞA, KAZIM YALÇIN
dc.contributor.authorsTuranli, Beste; Karagoz, Kubra; Gulfidan, Gizem; Sinha, Raghu; Mardinoglu, Adil; Arga, Kazim Yalcin
dc.date.accessioned2022-03-10T15:25:30Z
dc.date.accessioned2026-01-11T15:08:44Z
dc.date.available2022-03-10T15:25:30Z
dc.date.issued2018
dc.description.abstractA complex framework of interacting partners including genetic, proteomic, and metabolic networks that cooperate to mediate specific functional phenotypes drives human biological processes. Recent technological and analytical advances in omic sciences allow the identification and elucidation of reprogramming biological functions in response to perturbations in cells and tissues. To understand such a complex system, biological networks are generated to reduce the complexity into relatively simple models, and the integration of these molecular networks from different perspectives is implemented for a holistic interpretation of the entire system. Ultimately, network-based methods will effectively facilitate the development and improvement of precision medicine by directing therapies based on the underlying biology of a given patient's disease. The goal of precision medicine is to identify novel therapeutic strategies that can be optimized for each disease type or each patient based on the underlying genetic, environmental, and lifestyle factors. Pharmaco-omics analyses based on an integration of pharmacology and various omics data types can be employed to develop effective treatment strategies using particular drugs and doses that are tailored to each individual. In the current review, we first present the core elements of network-based systems biology in the context of pharmaco-omics followed by integration of multi-omics data using various biological networks. Next, we provide an opening into precise medicine and drug targeting based on network approaches. Lastly, we review the current significant efforts as well as the accomplishments and limitations in precise drug targeting with the utility of network-based guided drug discovery methods for effective treatment of breast cancer.
dc.identifier.doi10.2174/1381612824666181106095959
dc.identifier.eissn1873-4286
dc.identifier.issn1381-6128
dc.identifier.pubmed30398107
dc.identifier.urihttps://hdl.handle.net/11424/220267
dc.identifier.wosWOS:000455871200006
dc.language.isoeng
dc.publisherBENTHAM SCIENCE PUBL LTD
dc.relation.ispartofCURRENT PHARMACEUTICAL DESIGN
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDrug discovery
dc.subjectdrug repositioning
dc.subjectnetwork-based
dc.subjectprecision medicine
dc.subjectbreast cancer
dc.subjectpharmaco-omics
dc.subjectNEGATIVE BREAST-CANCER
dc.subjectCOMPREHENSIVE MOLECULAR PORTRAITS
dc.subjectPROTEIN-PROTEIN INTERACTIONS
dc.subjectTHERAPEUTIC TARGET DATABASE
dc.subjectGENE-COEXPRESSION NETWORK
dc.subjectPLASMA MANNOSE LEVELS
dc.subjectWEB SERVER
dc.subjectINTERACTION PREDICTION
dc.subjectMETABOLIC NETWORK
dc.subjectSYSTEMS BIOLOGY
dc.titleA Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine
dc.typereview
dspace.entity.typePublication
oaire.citation.endPage3790
oaire.citation.issue32
oaire.citation.startPage3778
oaire.citation.titleCURRENT PHARMACEUTICAL DESIGN
oaire.citation.volume24

Files